TY - JOUR
T1 - An Extensively Hydrolyzed Formula Supplemented with Two Human Milk Oligosaccharides Modifies the Fecal Microbiome and Metabolome in Infants with Cow’s Milk Protein Allergy
AU - Boulangé, Claire L.
AU - Pedersen, Helle K.
AU - Martin, Francois Pierre
AU - Siegwald, Léa
AU - Pallejà Caro, Albert
AU - Eklund, Aron C.
AU - Jia, Wei
AU - Zhang, Huizhen
AU - Berger, Bernard
AU - Sprenger, Norbert
AU - Heine, Ralf G.
AU - CINNAMON Study Investigator Group
N1 - Funding information:
This study was funded by Nestlé Health Science, Société des Produits Nestlé S.A., Vevey, Switzerland.
Publisher Copyright:
© 2023 by the authors.
PY - 2023/7/2
Y1 - 2023/7/2
N2 - Cow’s milk protein allergy (CMPA) is a prevalent food allergy among infants and young children. We conducted a randomized, multicenter intervention study involving 194 non-breastfed infants with CMPA until 12 months of age (clinical trial registration: NCT03085134). One exploratory objective was to assess the effects of a whey-based extensively hydrolyzed formula (EHF) supplemented with 2′-fucosyllactose (2′-FL) and lacto-N-neotetraose (LNnT) on the fecal microbiome and metabolome in this population. Thus, fecal samples were collected at baseline, 1 and 3 months from enrollment, as well as at 12 months of age. Human milk oligosaccharides (HMO) supplementation led to the enrichment of bifidobacteria in the gut microbiome and delayed the shift of the microbiome composition toward an adult-like pattern. We identified specific HMO-mediated changes in fecal amino acid degradation and bile acid conjugation, particularly in infants commencing the HMO-supplemented formula before the age of three months. Thus, HMO supplementation partially corrected the dysbiosis commonly observed in infants with CMPA. Further investigation is necessary to determine the clinical significance of these findings in terms of a reduced incidence of respiratory infections and other potential health benefits.
AB - Cow’s milk protein allergy (CMPA) is a prevalent food allergy among infants and young children. We conducted a randomized, multicenter intervention study involving 194 non-breastfed infants with CMPA until 12 months of age (clinical trial registration: NCT03085134). One exploratory objective was to assess the effects of a whey-based extensively hydrolyzed formula (EHF) supplemented with 2′-fucosyllactose (2′-FL) and lacto-N-neotetraose (LNnT) on the fecal microbiome and metabolome in this population. Thus, fecal samples were collected at baseline, 1 and 3 months from enrollment, as well as at 12 months of age. Human milk oligosaccharides (HMO) supplementation led to the enrichment of bifidobacteria in the gut microbiome and delayed the shift of the microbiome composition toward an adult-like pattern. We identified specific HMO-mediated changes in fecal amino acid degradation and bile acid conjugation, particularly in infants commencing the HMO-supplemented formula before the age of three months. Thus, HMO supplementation partially corrected the dysbiosis commonly observed in infants with CMPA. Further investigation is necessary to determine the clinical significance of these findings in terms of a reduced incidence of respiratory infections and other potential health benefits.
KW - amino acids
KW - bile acids
KW - fecal community type
KW - human milk oligosaccharides
KW - metabolomics
KW - metagenomics
KW - microbiome
KW - short-chain fatty acids
UR - http://www.scopus.com/inward/record.url?scp=85165951279&partnerID=8YFLogxK
U2 - 10.3390/ijms241411422
DO - 10.3390/ijms241411422
M3 - Journal article
C2 - 37511184
AN - SCOPUS:85165951279
SN - 1661-6596
VL - 24
JO - International Journal of Molecular Sciences
JF - International Journal of Molecular Sciences
IS - 14
M1 - 11422
ER -